Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

French biobank aims to unlock secrets of rare brain vessel diseases

NCT ID NCT07650110

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will collect blood samples and medical information from 600 adults with rare diseases affecting blood vessels in the brain and eye, such as CADASIL and cavernous angioma. The goal is to create a long-term biobank that researchers can use to find biomarkers and better understand how these diseases progress. Participants will provide samples and data over time, but this study does not test any new treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2038

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For the group of patients with MVCR: * Patients aged between 18 and 80 years at the time of inclusion * Diagnosis confirmed by the detection of a pathogenic mutation in the NOTCH3 gene characteristic of CADASIL, or in another gene responsible for other forms of monogenic cSVD (such as the COL4A1, COL4A2 and HTRA1 genes) or a confirmed diagnosis of MOYA-MOYA (arteriography and/or genetic testing) or cavernoma, cerebral venous thrombosis or a cerebral vascular malformation, including cavernomas * Covered by social security or an equivalent scheme * Written consent. * Patient included in the MVCR cohort For control group * Subject aged between 18 and 80 at the time of inclusion. * Written consent. * Blood pressure \< 140/90 mmHg without treatment or \< 130/80 mmHg if treated and stable for ≥3 months * Covered by social security or a similar scheme * Strictly normal neurological examination (NIHSS=0; no focal deficit) * Normal cognitive examination: MMSE ≥ 26 Exclusion criteria : Common exclusion criteria for patients and control subjects: * A person referred to in Articles L. 1121-5 to L. 1121-8 and L. 1122-12 of the Public Health Code, defined as: * Pregnant women, women in labour or breastfeeding women * Persons deprived of their liberty by judicial or administrative decision * Persons hospitalised without consent and not subject to a legal protection measure, and persons admitted to a health or social care facility for purposes other than research * Minors * Adults subject to a legal protection measure (guardianship, curatorship or judicial protection), adults unable to give consent and not subject to a legal protection measure * Individuals subject to a withdrawal period for another research study * Patients participating in another interventional research study * Acute or chronic infectious disease Specific exclusion criteria for control subjects * Any identified extra- or intracranial vascular pathology requiring specific management * Known cardiovascular disease (coronary artery disease, arterial disease, atrial fibrillation, heart failure) * Neurological history: stroke, TIA, intracranial haemorrhage, meningitis/encephalitis, head injury with loss of consciousness \>30 mins, * Multiple sclerosis, neurodegenerative disease, active epilepsy, * Current or former smoking (more than 10 pack-years) * Diabetes * Antithrombotic or lipid-lowering treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cadasil are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.